A Phase 3, Double-Blind, Randomized Study of Zolbetuximab in Combination with
Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of
Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction
Adenocarcinoma in Participants Whose Tumors are HER2-negative, Claudin (CLDN)
18.2-positive and PD-L1-positive
